Abstract 56P
Background
Inhibition of HIF-2α has had a substantial impact on the treatment paradigm for cancer patients with germline mutations in VHL. Preclinically, selective HIF-2α inhibitors demonstrate dramatic anti-tumor effects in xenograft models in which HIF-2α is a molecularly defined tumorigenic driver. However, therapeutic application of HIF-2α inhibitors beyond VHL-mutated clear cell renal cell carcinoma remains to be seen. In contrast to HIF-1α, HIF-2α has a more selective expression profile accompanying tailored regulons that may guide indications of interest.
Methods
The potential therapeutic benefit of HIF-2α inhibition in various oncology indications was investigated using bioinformatic, in vitro, and in vivo approaches. In mice, the role of HIF-2α in hepatocellular carcinoma (HCC) was investigated using an autochthonous high-fat diet carcinogen-induced tumor model.
Results
Consistent with the mechanism of action, inhibition of HIF-2α in various cell lines did not attenuate cell growth in 2D culture. However, significant alterations in the hypoxic gene signatures were detected, with substantial variation in HIF-2α-dependence. HIF-2α-specific gene signatures derived using pharmacological inhibition or genetic deletion applied to available datasets predicted poorer survival in multiple cancer indications, including renal (as validation) and liver. In an HCC mouse model, mice with deletion of HIF-2α in hepatocytes had significantly reduced number and size of liver nodules. These effects were apparent upon deletion of HIF-2α from birth or after tumors were established. Finally, mice treated with a HIF-2α inhibitor after tumor formation also had significantly decreased tumor burden.
Conclusions
HIF-2α plays a distinct and differential role in the transcriptional response to hypoxia in different tissue types and cell lines. In vivo data suggest that HIF-2α may contribute to the formation and progression of HCC, supporting clinical investigation of HIF-2α inhibition beyond ccRCC. AB521 is a potent and selective inhibitor that has been evaluated in healthy volunteers and is progressing through a phase Ib clinical trial in cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Arcus Biosciences, Inc.
Funding
Arcus Biosciences, Inc.
Disclosure
K.S. Gauthier, D. Piovesan, S. Cho,K.V. Lawson, K. Liao, P. Foster, T. Cheng, M. Walters: Financial Interests, Institutional, Stocks/Shares: Arcus Biosciences; Financial Interests, Institutional, Full or part-time Employment: Arcus Biosciences. Y. Shah: Financial Interests, Institutional, Funding: Arcus Biosciences. All other authors have declared no conflicts of interest.
Resources from the same session
97P - Bcl-xL prevents the arginine starvation induced by PEGylated arginine deiminase (ADI-PEG20) from inducing apoptosis
Presenter: Brian Van Tine
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Cationic dendrimers as prospective vehicles of therapeutic nucleic acids into tumor cells: Approaches, advantages and challenges
Presenter: Nadezhda Knauer
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Quantitative indicators of TREC and KREC excision rings in malignant neoplasms
Presenter: Alexander Sultanbaev
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
Presenter: Gulsah Nomak
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Prediction of radiation responses in patients with locally advanced rectal cancer with a patient-derived organoid-based radiosensitivity model
Presenter: Samart Phuwapraisirisan
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - Co-expression analysis of genes encoding proteasome subunits and XPO1-related proteins in the Cancer Genome Atlas (TCGA) and the Gene Tissue Expression (GTEx) databases as a tool to devise new treatment strategies
Presenter: Vito Spataro
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - Microsomal triglyceride transfer protein as a prognostic and therapeutic marker for brain cancer
Presenter: Ryuk Jun Kwon
Session: Cocktail & Poster Display session
Resources:
Abstract
104P - Choline transporter-like protein 1 is a novel molecular target for the treatment of hepatocellular carcinoma
Presenter: Masato Inazu
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Knockout of lncRNA-CCAT1 with the use of CRISPR-Cas9 system and G7 PAMAM dendrimers influences apoptosis and proliferations of NSCLC cells
Presenter: Mateusz Iwanski
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Censoring imbalance in ACIS trial for prostate cancer
Presenter: Noa Zimhony-Nissim
Session: Cocktail & Poster Display session
Resources:
Abstract